Tine Kold Olesen

The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer

Laurence Klotz, L Boccon-Gibod, Neal D. Shore et al. · British Journal of Urology · 2008 · 614 citations · Full text

Medicine, Oncology, Pharmacology +17

Cardiovascular Morbidity Associated with Gonadotropin Releasing Hormone Agonists and an Antagonist

Peter C. Albertsen, Laurence Klotz, Bertrand Tombal et al. · European Urology · 2013 · 338 citations

Medicine, Endocrinology, Pharmacology +14

A Phase III Extension Trial With a 1-Arm Crossover From Leuprolide to Degarelix: Comparison of Gonadotropin-Releasing Hormone Agonist and Antagonist Effect on Prostate Cancer

E. David Crawford, Bertrand Tombal, Kurt Miller et al. · The Journal of Urology · 2011 · 153 citations

Medicine, Oncology, Pharmacology +16

Additional Analysis of the Secondary End Point of Biochemical Recurrence Rate in a Phase 3 Trial (CS21) Comparing Degarelix 80mg Versus Leuprolide in Prostate Cancer Patients Segmented by Baseline Characteristics

Bertrand Tombal, Kurt Miller, L Boccon-Gibod et al. · European Urology · 2009 · 147 citations

Medicine, Oncology, Pharmacology +8

Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial

Renato D. Lópes, Celestia S. Higano, Susan F. Slovin et al. · Circulation · 2021 · 143 citations · Full text

Medicine, Endocrinology, Pharmacotherapy +13